Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.80 |
| ▸ | CASP3 | P42574 | 1/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.80 |
| ▸ | AOC1 | P19801 | 2/20 | 0.68 |
| ▸ | MAOB | P27338 | 3/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17151556 | 0.89 | KIF11 (1.00) | KIF11CASP3KCNH2AOC1MAOB | |
| SCHEMBL3625650 | 0.89 | KIF11 (1.00) | KIF11CASP3KCNH2AOC1MAOB | |
| SCHEMBL3624174 | 0.89 | KIF11 (1.00) | KIF11CASP3KCNH2MAOBNT5E | |
| SCHEMBL3624192 | 0.84 | KIF11 (0.78) | KIF11CASP3KCNH2MAOBKDM4E | |
| SCHEMBL3846014 | 0.79 | KIF11 (0.78) | KIF11CASP3KCNH2AOC1MAOB | |
| SCHEMBL3624136 | 0.78 | KIF11 (0.81) | KIF11CASP3KCNH2 | |
| SCHEMBL13588202 | 0.78 | KIF11 (0.79) | KIF11CASP3KCNH2MAOBNT5E | |
| SCHEMBL3621249 | 0.78 | KIF11 (0.80) | KIF11CASP3KCNH2AOC1MAOB | |
| SCHEMBL3616984 | 0.77 | KIF11 (0.79) | KIF11CASP3KCNH2MAOBMAOA | |
| SCHEMBL3626735 | 0.77 | KIF11 (1.00) | KIF11CASP3KCNH2MAOBNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150352114-A1 | MITOTIC KINESIN Eg5 INHIBITING ANTICANCER AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352114-A1 | MITOTIC KINESIN Eg5 INHIBITING ANTICANCER AGENTS | KIF15, KIF5B, KIF18A | KIF11 9/4885CASP3 1487/4885KCNH2 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.